Please use this identifier to cite or link to this item:
https://doi.org/10.1016/j.gore.2018.01.009
Title: | Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer | Authors: | Ngoi, NYL Heong, V Lee, XW Huang, YQ Thian, YL Choo, BA Lim, D Lim, YW Lim, SE Ilancheran, A Soong, R Tan, DSP |
Keywords: | Biomakers Cervical cancer Immune checkpoint inhibition Pembrolizumab |
Issue Date: | 1-May-2018 | Publisher: | Elsevier BV | Citation: | Ngoi, NYL, Heong, V, Lee, XW, Huang, YQ, Thian, YL, Choo, BA, Lim, D, Lim, YW, Lim, SE, Ilancheran, A, Soong, R, Tan, DSP (2018-05-01). Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant advanced cervical cancer. Gynecologic Oncology Reports 24 : 1-May. ScholarBank@NUS Repository. https://doi.org/10.1016/j.gore.2018.01.009 | Abstract: | Optimal treatment for advanced cervical cancer after first line chemotherapy remains undefined. Immune checkpoint inhibition with pembrolizumab, a programmed cell death protein 1(PD-1) inhibitor, is under investigation. We analyzed the micro-environmental and molecular genetic profile of tumors from 4 patients with metastatic cervical cancer treated with off-label second-line pembrolizumab in an effort to identify predictive biomarkers. All patients received 2 mg/kg of pembrolizumab, 3-weekly until disease progression. Immunohistochemistry(IHC) for PD-1, PD-L1, CD3 and CD8, as well as next generation sequencing (NGS) for 50 cancer-related genes were performed on tumor samples. All patients tolerated treatment well with no discontinuation of treatment due to toxicity. One patient experienced dramatic and prolonged partial response, and remains stable on pembrolizumab with a progression free survival (PFS) of 21 months at the time of reporting of this series. Three patients experienced disease progression as best response. In the exceptional responder, there was no tumoral expression of PD-L1, however, combined positive score (CPS) for PD-L1 was 1 and we identified somatic mutations in ERBB4(R612W), PIK3CA(E542K) and RB1(E365K). In 2 patients, despite progressive disease defined by RECIST v1.1, symptom stabilization on pembrolizumab was observed. The tumors of both patients had PD-1 expression in ≥1% of stromal lymphocytes. All patients with response or clinical benefit had CPS for PD-L1 ≥ 1. NGS revealed PIK3CA mutations in 3 tumors. Pembrolizumab is a promising therapeutic option in advanced cervical cancer. Further evaluation of biomarkers may guide optimal patient selection. | Source Title: | Gynecologic Oncology Reports | URI: | https://scholarbank.nus.edu.sg/handle/10635/206422 | ISSN: | 23525789 | DOI: | 10.1016/j.gore.2018.01.009 |
Appears in Collections: | Staff Publications Elements |
Show full item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
Tumor molecular profiling of responders and non-responders following pembrolizumab monotherapy in chemotherapy resistant adv.pdf | 347.86 kB | Adobe PDF | OPEN | None | View/Download |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.